Using NGAL to guide fluids and start kidney-filtering in children
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether measuring a urine protein called NGAL can help doctors choose the right fluid amount and decide when to start a kidney-filtering treatment called CRRT in critically ill children with kidney injury. If it works, it may help treat kidney problems sooner and more safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are being cared for in the pediatric intensive care unit (PICU)
- Your team says your Renal Angina Index (RAI) is 8 or higher
- Your urine NGAL level is 150 ng/mL or higher
- You have a urine catheter in place to collect urine
- You do not have signs of low body fluid (volume depletion)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to find children in the pediatric ICU who are at risk for serious kidney injury early, so doctors can start treatment sooner. Your child's kidney stress markers will be checked from a blood or urine sample.
This study tests a urine test that may help detect kidney injury early in ICU patients. Early detection could lead to quicker treatment and better outcomes.
This trial tests a special device that filters parts of the blood to calm inflammation in people with severe acute kidney injury in the ICU. It may help improve recovery and reduce complications by “deactivating” certain immune cells.
This study looks at how to safely remove excess fluid from patients in the ICU who have sudden kidney failure and are on a special blood-filtering machine (CRRT). Researchers want to understand which patients have trouble tolerating fluid removal and how to prevent complications.
This study looks at how kidney ultrasound can help monitor critically ill patients who need continuous dialysis for acute kidney injury. The results may help doctors better manage treatment.
This trial studies whether a blood test called delta C-cistatin can help doctors predict when patients can safely stop continuous kidney dialysis after acute kidney injury.
Hear when a new Acute Kidney Injury trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.